MIFCOR, Inc.
Biotechnology - New Haven, Connecticut, United States
MIFCOR, Inc. Employees
MIFCOR, Inc. Details
Currently, there is no available drug that reduces tissue death during heart attack, one of the leading causes of death worldwide. MIFCOR is addressing this great need by developing a first-in-class biologic therapeutic for protecting tissue from cell death following reduced blood flow (ischemia). Our therapeutic, MIF-2, takes advantage of breakthrough science: by targeting a novel biological pathway, it protects tissue from ischemia-induced death. We have made concrete steps toward commercialization of this revolutionary therapy, including successfully executing an exclusive option on an IP portfolio, building a business plan, assembling a team of world-class advisors, and getting interest from potential investors.
MIFCOR, Inc. Technologies
Email Providers
Gmail
Other
Google Apps